Positive News Sentiment NASDAQ:VBIV VBI Vaccines Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding VBI Vaccines Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.82 +0.01 (+1.22%) (As of 07/5/2022 05:46 PM ET) Add Compare Share Today's Range$0.78▼$0.8450-Day Range$0.66▼$1.3552-Week Range$0.64▼$3.81Volume1.24 million shsAverage Volume3.67 million shsMarket Capitalization$211.33 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability VBI Vaccines MarketRank™ ForecastAnalyst RatingStrong Buy3.50 Rating ScoreUpside/Downside633.2% Upside$6.00 Price TargetShort InterestBearish8.89% of Float Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.27) to ($0.21) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.19 out of 5 starsMedical Sector282nd out of 1,426 stocksPharmaceutical Preparations Industry130th out of 682 stocks 3.8 Analyst's Opinion Consensus RatingVBI Vaccines has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, VBI Vaccines has a forecasted upside of 633.2% from its current price of $0.82.Amount of Analyst CoverageVBI Vaccines has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.89% of the float of VBI Vaccines has been sold short.Short Interest Ratio / Days to CoverVBI Vaccines has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in VBI Vaccines has recently increased by 5.92%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVBI Vaccines does not currently pay a dividend.Dividend GrowthVBI Vaccines does not have a long track record of dividend growth. Previous Next 3.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVBI Vaccines has received a 51.81% net impact score from Upright. VBI Vaccines seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for VBI Vaccines is -0.75. Previous Next 2.7 News and Social Media Coverage News SentimentVBI Vaccines has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for VBI Vaccines this week, compared to 1 article on an average week.Search Interest32 people have searched for VBIV on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added VBI Vaccines to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VBI Vaccines insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.00% of the stock of VBI Vaccines is held by insiders.Percentage Held by Institutions43.24% of the stock of VBI Vaccines is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for VBI Vaccines are expected to grow in the coming year, from ($0.27) to ($0.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VBI Vaccines is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VBI Vaccines is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVBI Vaccines has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VBIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter. Email Address About VBI Vaccines (NASDAQ:VBIV) StockVBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.Read More VBIV Stock News HeadlinesJune 28, 2022 | seekingalpha.comVBI Vaccines boasts of new follow-up data for hepatitis B vaccine over GSK rivalJune 28, 2022 | finance.yahoo.comVBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022June 22, 2022 | finance.yahoo.comVBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of GlioblastomaJune 17, 2022 | seekingalpha.comVBI Vaccines: Recent VBI-1901 Data Supports My Bull ThesisJune 7, 2022 | finance.yahoo.comVBI Vaccines to Participate in the Jefferies Healthcare ConferenceJune 6, 2022 | finance.yahoo.comVBI Vaccines Presents Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at the 2022 ASCO Annual MeetingMay 26, 2022 | finance.yahoo.comVBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022May 19, 2022 | finance.yahoo.comVBI Vaccines Presented Health Economics and Outcomes Research for PreHevbrio™ at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022May 12, 2022 | finance.yahoo.comIs VBI Vaccines (NASDAQ:VBIV) Weighed On By Its Debt Load?May 9, 2022 | finance.yahoo.comVBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate UpdateMay 5, 2022 | finance.yahoo.comDenali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue EstimatesMay 2, 2022 | seekingalpha.comVBI Vaccines stock rises as hepatitis B shot PreHevbri gets approval in EUMay 2, 2022 | finance.yahoo.comVBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B VaccineApril 28, 2022 | finance.yahoo.comVBI Vaccines Announces Data from VBI-1901 in Recurrent Glioblastoma Patients Selected for Poster Discussion at the 2022 ASCO Annual MeetingApril 11, 2022 | finance.yahoo.comWhen Can We Expect A Profit From VBI Vaccines Inc. (NASDAQ:VBIV)?April 5, 2022 | finance.yahoo.comVBI Vaccines To Start Clinical Study Of Pan-Coronavirus Vaccine Candidate This YearApril 5, 2022 | finance.yahoo.comVBI Vaccines Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus ProgramMarch 29, 2022 | seekingalpha.comVBI Vaccines launches Hepatitis B vaccine in U.S.March 29, 2022 | finance.yahoo.comVBI Vaccines Announces PreHevbrio™ is Now Available in the United States for the Prevention of Hepatitis B in AdultsMarch 15, 2022 | finance.yahoo.comVBI Vaccines to Participate in the 32nd Annual Oppenheimer Healthcare ConferenceMarch 7, 2022 | finance.yahoo.comQualTek Names New Independent Board Appointees to its Board of DirectorsMarch 7, 2022 | finance.yahoo.comVBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2021, Provides Corporate Update and Outlook for 2022February 25, 2022 | marketwatch.comVBI Vaccines Gets CHMP Positive Opinion for Hepatitis B VaccineFebruary 25, 2022 | seekingalpha.comVBI Vaccines wins European recommendation for Hep B vaccineFebruary 25, 2022 | finance.yahoo.comVBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European UnionSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VBIV CUSIPN/A CIK764195 Webwww.vbivaccines.com Phone(617) 830-3031FaxN/AEmployees149Year FoundedN/ACompany Calendar Last Earnings5/09/2022Today7/06/2022Next Earnings (Estimated)8/01/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+633.2%Consensus RatingStrong Buy Rating Score (0-4)3.5 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,750,000.00 Net Margins-16,087.72% Pretax Margin-16,087.72% Return on Equity-48.77% Return on Assets-34.40% Debt Debt-to-Equity Ratio0.19 Current Ratio3.31 Quick Ratio3.19 Sales & Book Value Annual Sales$630,000.00 Price / Sales335.45 Cash FlowN/A Price / Cash FlowN/A Book Value$0.56 per share Price / Book1.46Miscellaneous Outstanding Shares258,260,000Free Float237,596,000Market Cap$211.33 million OptionableOptionable Beta1.98 VBI Vaccines Frequently Asked Questions Should I buy or sell VBI Vaccines stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "strong buy" VBI Vaccines stock. View analyst ratings for VBI Vaccines or view top-rated stocks. What is VBI Vaccines' stock price forecast for 2022? 2 analysts have issued twelve-month price objectives for VBI Vaccines' stock. Their VBIV stock forecasts range from $6.00 to $6.00. On average, they predict VBI Vaccines' stock price to reach $6.00 in the next year. This suggests a possible upside of 633.2% from the stock's current price. View analysts' price targets for VBI Vaccines or view top-rated stocks among Wall Street analysts. How has VBI Vaccines' stock performed in 2022? VBI Vaccines' stock was trading at $2.34 at the beginning of 2022. Since then, VBIV stock has decreased by 65.0% and is now trading at $0.8183. View the best growth stocks for 2022 here. When is VBI Vaccines' next earnings date? VBI Vaccines is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022. View our earnings forecast for VBI Vaccines. How were VBI Vaccines' earnings last quarter? VBI Vaccines Inc. (NASDAQ:VBIV) released its quarterly earnings data on Monday, May, 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting analysts' consensus estimates of ($0.08). The biopharmaceutical company had revenue of $0.13 million for the quarter, compared to analysts' expectations of $0.13 million. VBI Vaccines had a negative net margin of 16,087.72% and a negative trailing twelve-month return on equity of 48.77%. View VBI Vaccines' earnings history. Who are VBI Vaccines' key executives? VBI Vaccines' management team includes the following people: Mr. Jeffery R. Baxter F.C.M.A., FCMA, Pres, CEO & Director (Age 61, Pay $1.04M)Mr. Christopher McNulty, CFO, Head of Bus. Devel. & Director (Age 45)Dr. David Evander Anderson, Chief Scientific Officer (Age 52, Pay $605.07k)Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D., Chief Medical Officer (Age 67, Pay $652.09k)Nicole Anderson, Director of Corp. Communications & Investor RelationsMs. Athena Kartsaklis, Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer (Age 57)Ms. Nell Beattie, Chief Bus. Officer (Age 34) (LinkedIn Profile)Mr. Avi Mazaltov, Global Head of Manufacturing & GM of SciVac (Age 60)Mr. Misha Nossov, Sr. VP of Market Access & CommercialMr. T. Adam Buckley, Sr. VP of Bus. Devel. (Age 46) Who are some of VBI Vaccines' key competitors? Some companies that are related to VBI Vaccines include ADVANZ PHARMA (CXRXF), Phibro Animal Health (PAHC), Design Therapeutics (DSGN), IGM Biosciences (IGMS), Nuvation Bio (NUVB), Avidity Biosciences (RNA), CinCor Pharma (CINC), Verve Therapeutics (VERV), Pharvaris (PHVS), Theravance Biopharma (TBPH), Catalyst Pharmaceuticals (CPRX), Erasca (ERAS), PMV Pharmaceuticals (PMVP), Kiniksa Pharmaceuticals (KNSA) and Nektar Therapeutics (NKTR). View all of VBIV's competitors. What other stocks do shareholders of VBI Vaccines own? Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie (). What is VBI Vaccines' stock symbol? VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV." How do I buy shares of VBI Vaccines? Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is VBI Vaccines' stock price today? One share of VBIV stock can currently be purchased for approximately $0.82. How much money does VBI Vaccines make? VBI Vaccines (NASDAQ:VBIV) has a market capitalization of $211.33 million and generates $630,000.00 in revenue each year. The biopharmaceutical company earns $-69,750,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis. How many employees does VBI Vaccines have? VBI Vaccines employs 149 workers across the globe. How can I contact VBI Vaccines? VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The official website for VBI Vaccines is www.vbivaccines.com. The biopharmaceutical company can be reached via phone at (617) 830-3031 or via email at ir@vbivaccines.com. This page (NASDAQ:VBIV) was last updated on 7/6/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
